# Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: combined retrospective analyses of two real-world databases and in vitro data.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12219783</article-id><article-id pub-id-type="pmid">40598449</article-id>
<article-id pub-id-type="publisher-id">4130</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04130-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: combined retrospective analyses of two real-world databases and in vitro data</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Niimura</surname><given-names>Takahiro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Goda</surname><given-names>Mitsuhiro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nakano</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kajihara</surname><given-names>Toshiki</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yahara</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hirabayashi</surname><given-names>Aki</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Miyata</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ikai</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Shinohara</surname><given-names>Motoko</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Minato</surname><given-names>Yusuke</given-names></name><address><email>yusuke.minato@fujita-hu.ac.jp</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Suzuki</surname><given-names>Masato</given-names></name><address><email>suzuki-m@niid.go.jp</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ishizawa</surname><given-names>Keisuke</given-names></name><address><email>ishizawa@tokushima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/044vy1d05</institution-id><institution-id institution-id-type="GRID">grid.267335.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 1092 3579</institution-id><institution>Department of Clinical Pharmacology and Therapeutics, </institution><institution>University of Tokushima Graduate School of Biomedical Sciences, </institution></institution-wrap>Tokushima, Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021ph5e41</institution-id><institution-id institution-id-type="GRID">grid.412772.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 2191</institution-id><institution>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, </institution></institution-wrap>Tokushima, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03t78wx29</institution-id><institution-id institution-id-type="GRID">grid.257022.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 8711 3200</institution-id><institution>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical and Heath Sciences, </institution><institution>Hiroshima University, </institution></institution-wrap>Hiroshima, Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001ggbx22</institution-id><institution-id institution-id-type="GRID">grid.410795.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2220 1880</institution-id><institution>Antimicrobial Resistance Research Center, </institution><institution>National Institute of Infectious Diseases, Japan Institute for Health Security, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/046f6cx68</institution-id><institution-id institution-id-type="GRID">grid.256115.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 798X</institution-id><institution>Center for Infectious Disease Research, </institution><institution>Fujita Health University, </institution></institution-wrap>Aichi, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021ph5e41</institution-id><institution-id institution-id-type="GRID">grid.412772.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 2191</institution-id><institution>Department of Pharmacy, </institution><institution>Tokushima University Hospital, </institution></institution-wrap>Tokushima, Japan </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>396</elocation-id><history><date date-type="received"><day>10</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Flomoxef and cefmetazole have been reported to be effective against broad-spectrum &#x003b2;-lactamase-producing bacteria and have gained attention as a potential alternative to carbapenems. This study aimed to compare the efficacy of these two drugs in treating urinary tract infection (UTI) by integrating in vitro data and two real-world databases.</p></sec><sec><title>Methods</title><p id="Par2">The susceptibility rates of third-generation cephalosporin-resistant <italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic> to flomoxef and cefmetazole were compared using comprehensive national antimicrobial resistance surveillance data. Combined antimicrobial activities against an extended-spectrum beta-lactamase (ESBL)-producing multidrug-resistant bacterial strain were tested by diagonal measurement of n-way drug interactions. The effectiveness of the two drugs in treating UTIs was compared using hospital stay duration data obtained from the Japan Medical Data Center (JMDC) Claims Database.</p></sec><sec><title>Results</title><p id="Par3">Third-generation cephalosporin-resistant <italic>E. coli</italic> and <italic>K. pneumoniae</italic>, including ESBL-producing strains, were similarly susceptible to flomoxef and cefmetazole. In vitro assessment against an ESBL-producing multidrug-resistant strain revealed similar antimicrobial interaction patterns. JMDC Claims data analysis showed that the median hospital stay was 11 (95% confidence interval [CI]: 11&#x02013;11) and 4 (95% CI: 3&#x02013;5) days in the cefmetazole and flomoxef groups, respectively (log-rank test, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). Moreover, the flomoxef group demonstrated a significantly lower frequency of adverse events such as <italic>C. difficile</italic> infection and renal failure.</p></sec><sec><title>Conclusions</title><p id="Par4">The effectiveness of flomoxef is comparable to that of cefmetazole in treating UTIs without major complications. Thus, flomoxef is a viable treatment option for UTIs in locales with a high prevalence of ESBL-producing strains.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04130-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cefmetazole</kwd><kwd>Flomoxef</kwd><kwd>Urinary tract infection</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>23H02634</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP23gm1610013</award-id><award-id>JP23wm0325037</award-id><award-id>JP23wm0325037</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003478</institution-id><institution>Ministry of Health, Labour and Welfare</institution></institution-wrap></funding-source><award-id>25HA1004</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par24">The increase in extended-spectrum beta-lactamase (ESBL)-producing bacteria has complicated the treatment of urinary tract infections (UTIs) and intra-abdominal infections due to resistance to various classes of antimicrobials [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Currently, carbapenems are the preferred treatment option for severe infections caused by ESBL-producing bacteria. However, carbapenem-resistant strains have emerged and spread, which has raised interest in treatment strategies that spare carbapenems [<xref ref-type="bibr" rid="CR4">4</xref>].
</p><p id="Par25">Cefmetazole and flomoxef are antimicrobial agents that were originally developed in Japan. Cefmetazole is a cephamycin that has a broad spectrum of antibacterial activity against <italic>Enterobacterales</italic>, such as <italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic>, as well as anaerobic bacteria, and is widely indicated for the treatment of UTI and intra-abdominal infections [<xref ref-type="bibr" rid="CR5">5</xref>]. Flomoxef is an oxacephem that, like cefmetazole, is active against <italic>E. coli</italic>, <italic>K. pneumoniae</italic>, and other <italic>Enterobacterales</italic> and is indicated for the treatment of UTI and intra-abdominal infections [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Flomoxef has been approved in Japan, China, Taiwan, and South Korea and has been used in clinical practice since 1988 [<xref ref-type="bibr" rid="CR8">8</xref>]. Both cefmetazole and flomoxef have a methoxy group at the 7-position of cephalosporanic acid and are stable to hydrolysis by ESBL [<xref ref-type="bibr" rid="CR9">9</xref>]. Cefmetazole and flomoxef demonstrate in vitro efficacy against ESBL-producing bacteria and are of increasing clinical importance as carbapenem-sparing therapeutic options for infections caused by ESBL-producing <italic>Enterobacterales</italic> [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par26">Although accumulated clinical data have reported comparable effectiveness of cefmetazole with carbapenems against infections due to ESBL-producing bacteria, clinical data regarding flomoxef remain limited [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. To the best of our knowledge, no national study has compared the susceptibility rates of flomoxef and cefmetazole among ESBL-producing <italic>Enterobacterales</italic>. Furthermore, no large study has compared the effectiveness of treatment with flomoxef and cefmetazole. In recent years, the resistance rate of cefmetazole in ESBL-producing <italic>E. coli</italic> has been shown to be higher than that of flomoxef [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. However, cefmetazole is more widely used in clinical practice, and given the recent instability in antimicrobial supply [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], it would be beneficial to clarify the potential of flomoxef as a treatment option against ESBL-producing bacterial infections.</p><p id="Par27">This study aimed to compare the usefulness of the two drugs by integrating in vitro data using a retrospective analysis of two real-world databases (National claims database and Nosocomial infections surveillance database).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Antimicrobial susceptibility profile of <italic>E. coli</italic> and <italic>K. pneumoniae</italic> clinical isolates based on the national antimicrobial resistance surveillance data</title><p id="Par28">Data on bacterial isolates from inpatients in Japan between January 2014 and December 2021 were extracted from the national antimicrobial resistance surveillance program, the Japan Nosocomial Infections Surveillance (JANIS), which collects all routine microbiological diagnostic tests [<xref ref-type="bibr" rid="CR18">18</xref>]. The JANIS datacenter recommends that MIC data be collected using the broth dilution method. In principle, antimicrobial susceptibility test results obtained using the disk method are excluded from tabulation. Additionally, if the same organism is detected more than once in the same patient, duplicate entries will be processed during tabulation [<xref ref-type="bibr" rid="CR19">19</xref>]. A total of 2220 hospitals across Japan submitted their data to the JANIS database in 2021. We specifically targeted <italic>E. coli</italic> and <italic>K. pneumoniae</italic> due to their prevalence in UTIs. Data on antimicrobial susceptibility testing of isolates from urine and blood specimens were obtained, and the minimum inhibitory concentration (MIC) values of cefotaxime, cefmetazole, and flomoxef were analysed. We interpreted the MIC data for cefotaxime and cefmetazole using the 2023 Clinical and Laboratory Standards Institute (CLSI) criteria, which have remained unchanged since 2012. In this study, cefotaxime-resistant <italic>E. coli</italic> and <italic>K. pneumoniae</italic> isolates were considered as resistant to third-generation cephalosporins.</p><p id="Par29">This part of the study was approved by the Ministry of Health, Labour, and Welfare (approval number: 1025&#x02013;2) according to Article 32 of the Statistics Act.</p></sec><sec id="Sec4"><title>in vitro&#x000a0;drug interaction characterization</title><p id="Par30">To focus on the individual efficacy of cefmetazole and flomoxef, we evaluated the potential synergistic or antagonistic effects when various antimicrobials were used in combination. Drug interactions were assessed using the diagonal measurement of n-way drug interactions (DiaMOND) method as previously described [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. An ESBL-producing, multidrug-resistant uropathogenic <italic>E. coli</italic> clinical strain UPEC GU2019-E4 [<xref ref-type="bibr" rid="CR22">22</xref>] was used. Unless otherwise noted, bacterial cells were grown in a lysogeny broth medium at 37 &#x000b0;C under aerobic conditions. The bacterial cultures were diluted in fresh medium to an optical density at 600 nm (OD<sub>600</sub>) of 0.001, and 50 &#x003bc;L of the diluted culture was added to each well of a clear flat-bottom 384-well microplate. Antimicrobial agents were dispensed using a digital dispenser (Multidrop pico8 digital dispenser; Thermo Fisher). After 22-h incubation at 37 &#x000b0;C without shaking, OD<sub>600</sub> was measured using a microplate reader (Bio Tek Synergy HTX plate reader: Agilent). The fractional inhibitory concentration index (FICI) was used to evaluate the combination effect of the drugs. Dose&#x02013;response sampling for the combination was performed by measuring and calculating the 90% inhibition concentration (IC<sub>90</sub>) values for each drug separately and creating a dilution series of the combined drugs at half the concentration of each drug&#x02019;s IC<sub>90</sub> values. The growth inhibition assay was performed similarly to that for single drugs, and the OD<sub>600</sub> data obtained were used to calculate the IC<sub>90</sub>, which was defined as the observed IC<sub>90</sub>. The intersection of the line connecting the IC<sub>90</sub> values of each single drug and the diagonal line representing the dose response of the combination drug was defined as the expected IC<sub>90</sub>.</p></sec><sec id="Sec5"><title>Data source of the claims database analysis</title><p id="Par31">Data from April 2014 to November 2021 in the Japan Medical Data Center (JMDC) Claims Database were used for the study. This database contains inpatient and outpatient claims, as well as the Diagnosis Procedure Combination (DPC) practice data from several health insurance associations. The DPC system is a comprehensive reimbursement system for acute inpatient care introduced in Japan in 2003 [<xref ref-type="bibr" rid="CR23">23</xref>]. It is possible to extract diagnoses of injuries and diseases, drug prescriptions, weight, height, and activities of daily living (ADL) scores at the time of admission from the insurance claims and DPC practice data.</p><p id="Par32">This part of the study was approved by the Ethics Committee of Tokushima University Hospital (protocol number: 4492). This study was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology Reporting Guidelines for Cohort Studies.</p></sec><sec id="Sec6"><title>Study design of the claims database analysis</title><p id="Par33">Patients with a confirmed diagnosis of UTI on the date of first admission following the initiation of record collection from each patient&#x02019;s JMDC and who were prescribed cefmetazole or flomoxef on the same day were included. The diagnosis of UTI was based on the International Statistical Classification of Diseases and Related Health Problems 10 th Revision (ICD-10) Version 2016 of the World Health Organization (Additional File 1). The date of the first cefmetazole or flomoxef dose was set as the index date (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Certain patient groups were excluded: those not in the DPC wards, those without a UTI diagnosis on the antimicrobial prescription date, those who died within 24 h of admission, and those receiving both cefmetazole and flomoxef.<fig id="Fig1"><label>Fig. 1</label><caption><p>Analysis design of claim data analysis. Timeline for index date and associated time point. Abbreviations: JMDC, Japan Medical Data Center</p></caption><graphic xlink:href="12916_2025_4130_Fig1_HTML" id="MO1"/></fig></p><p id="Par34">Owing to the multiple outcomes and statistical methods used in this study, several analytic datasets were created: Dataset 1 comprised the dataset of all remaining patients after excluding those who met the exclusion criteria; Dataset 2 comprised only those patients who were discharged alive after excluding those who died during hospitalization; and Dataset 3 was created by 1:1 matching of patients administered cefmetazole and flomoxef by the propensity score for Dataset 2.</p></sec><sec id="Sec7"><title>Definition of baseline characteristics and complications</title><p id="Par35">Sex, age, body mass index (BMI), Barthel index, Japan coma scale (JCS), and various complications (sepsis, shock, and respiratory failure) were evaluated at the index date. BMI was classified as underweight (BMI &#x0003c;&#x02009;18.5 kg/m<sup>2</sup>), normal weight (BMI 18.5&#x02013;24.9 kg/m<sup>2</sup>), overweight (BMI 25.0&#x02013;29.9 kg/m<sup>2</sup>), obese (BMI &#x02265;&#x02009;30 kg/m<sup>2</sup>), and deficient, according to previous studies [<xref ref-type="bibr" rid="CR24">24</xref>]. The Barthel Index consists of 10 items: feeding (0&#x02013;10 points), bathing (0&#x02013;5 points), grooming (0&#x02013;5 points), dressing (0&#x02013;10 points), bowel control (0&#x02013;10 points), bladder control (0&#x02013;10 points), voiding (0&#x02013;10 points), chair movement (0&#x02013;15 points), walking (0&#x02013;15 points), and stair climbing (0&#x02013;10 points). A higher score indicated a higher degree of independence in the ADLs. The JCS categorizes consciousness into four major grades based on reactive eye-opening. Grade 0 signifies awake consciousness. Grades 1&#x02013;3, represented by a single digit, indicate awake status without any stimulus. Grades 10&#x02013;30, denoted by two digits, describe a state where the individual awakens with stimulus but reverts to the previous state once the stimulus is removed. Finally, grades 100&#x02013;300, expressed with three digits, correspond to a state where the individual does not arouse in response to any stimulus [<xref ref-type="bibr" rid="CR25">25</xref>]. The JCS has been reported to correlate well with the globally used Glasgow coma scale [<xref ref-type="bibr" rid="CR26">26</xref>]. The complications of sepsis, shock, and respiratory failure were evaluated based on the diagnoses listed in Additional File 2. The Charlson comorbidity index and history of diabetes were evaluated based on the diagnoses before the index date (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The Charlson comorbidity index was assigned to each patient according to a previous study [<xref ref-type="bibr" rid="CR27">27</xref>]. History of diabetes or urinary tract abnormalities was defined based on the ICD-10 codes (Additional File 3).</p></sec><sec id="Sec8"><title>Patient outcomes</title><p id="Par36">The primary effectiveness outcome was the number of days from the index date to discharge. Secondary effectiveness outcomes were defined as 28-day mortality after the index date and carbapenem use within 7 days after the index date. Safety outcomes were defined as gastrointestinal adverse events (AEs) (non-<italic>C. difficile</italic> diarrhoea, <italic>C. difficile</italic> infection), renal-related AEs (kidney failure and other kidney dysfunctions), and hypersensitivity symptoms (anaphylactic shock and rash) (Additional File 4). Gastrointestinal- and renal-related AEs were analysed 1 month after the index date, and hypersensitivity symptoms were analysed 2 days after the index date. AEs were defined based on the ICD-10 codes and drug use (Additional File 4).</p><p id="Par37">The primary effectiveness outcome was analysed using Datasets 2 and 3, and the secondary effectiveness outcomes were analysed using Dataset 1. Safety outcomes were analysed using Dataset 1.</p></sec><sec id="Sec9"><title>Statistical analyses</title><p id="Par38">Continuous variables are expressed as mean &#x000b1;&#x02009;standard deviation, while categorical variables are reported as percentages. The standardized mean difference was used to identify differences in patient backgrounds between the cefmetazole and flomoxef groups.</p><p id="Par39">Kaplan&#x02013;Meier analysis was used to estimate the primary effectiveness outcome, namely the time from the initiation of cefmetazole or flomoxef treatment to discharge alive, and log-rank tests were used to evaluate differences. Cox regression analysis was performed using age, sex, Charlson comorbidity index, Brinkman index, BMI, JCS, comorbidities (diabetes, sepsis, shock, respiratory failure, acute prostatitis, acute tubule-interstitial nephritis, cystitis), underlying urinary tract abnormalities, Barthel index, mechanical ventilation and dialysis on the day of admission, and prescription of vasopressors (epinephrine, norepinephrine, dopamine, dobutamine, and vasopressin) on the index date as covariates that may affect prognosis. Hazard ratios (HRs) for survival and discharge were calculated. Propensity score matching with 1:1 matching was performed to balance baseline characteristics. Matching was performed using nearest neighbour matching with a caliper of 0.05. The propensity score was calculated using age, sex, Charlson comorbidity index, Brinkman index, BMI, JCS, comorbidities (diabetes, sepsis, shock, respiratory failure, acute prostatitis, acute tubule-interstitial nephritis, cystitis), underlying urinary tract abnormalities, Barthel index, mechanical ventilation and dialysis on the day of admission, and prescription of vasopressors (epinephrine, norepinephrine, dopamine, dobutamine, and vasopressin) on the index date. Kaplan&#x02013;Meier analysis, log-rank test, and Cox regression analysis were performed on the crude and matched data. In the sensitivity analysis, we performed an inverse probability weighting (IPW) approach using the same covariates employed in the propensity score matching analysis to estimate stabilised weights through logistic regression model. The weights were applied to balance baseline characteristics across the comparison groups, and assess the treatment effects. This approach complemented our primary propensity score-matched analysis to evaluate the robustness of findings under different statistical assumptions.</p><p id="Par40">For the secondary effectiveness outcome, logistic regression analysis was performed with age, sex, Charlson comorbidity index, Brinkman index, BMI, JCS, comorbidities (diabetes, sepsis, shock, respiratory failure, acute prostatitis, acute tubule-interstitial nephritis, cystitis), underlying urinary tract abnormalities, Barthel index, mechanical ventilation and dialysis on the day of admission, and prescription of vasopressors (epinephrine, norepinephrine, dopamine, dobutamine, and vasopressin) on the index date as covariates. The odds ratios (ORs) for 28-day mortality and prescriptions of carbapenems were calculated.</p><p id="Par41">For safety outcomes, the frequencies were calculated and descriptively analysed for gastrointestinal, renal, hepatic, and hypersensitive AEs.</p><p id="Par42">Statistical tests were two-tailed, with a <italic>p</italic>&#x02009;&#x0003c; 0.05 considered statistically significant, and performed using R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec><sec id="Sec10"><title>Role of funding</title><p id="Par43">This work was supported by Japan Agency for Medical Research and Development (AMED) [grant number JP23wm0325037, JP24fk0108665, JP24fk0108683, JP24fk0108712, JP24fk0108642, JP24gm1610003, JP24wm0225029, JP24wm0225022, and JP23 gm1610013], JSPS KAKENHI Grant (23H02634, 23K27325), and Health Labour Sciences Research Grant, Ministry of Health, Labour and Welfare (25HA1004). The funders had no role in the study design; collection, analysis, and interpretation of data; writing of the report; or decision to submit for publication.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Antimicrobial susceptibility of <italic>E. coli</italic> and <italic>K. pneumoniae</italic> isolated from urine and blood against cefmetazole and flomoxef</title><p id="Par44">In total, 682,034 <italic>E. coli</italic> and 143,842 <italic>K. pneumoniae</italic> isolates from urine culture specimens, and 144,219 <italic>E. coli</italic> and 53,334 <italic>K</italic><italic>. pneumoniae</italic> isolates from blood culture specimens underwent antimicrobial susceptibility testing for both cefmetazole and flomoxef (Table <xref rid="Tab1" ref-type="table">1</xref>, Additional File 5). Among them, 1.4% of third-generation cephalosporin-resistant (3GC-R) <italic>E. coli</italic> isolates and 5.5% of 3GC-R <italic>K. pneumoniae</italic> isolates from urine had MICs of cefmetazole of &#x02265;&#x02009;64 mg/L. On the other hand, 1.0% of 3GC-R <italic>E. coli</italic> isolates and 3.0% of 3GC-R <italic>K. pneumoniae</italic> isolates had MICs of flomoxef of &#x02265;&#x02009;64 mg/L. Concerning blood culture specimens, 1.5% of 3GC-R <italic>E. coli</italic> isolates and 6.2% of 3GC-R <italic>K. pneumoniae</italic> isolates had MICs of cefmetazole of &#x02265;&#x02009;64 mg/L. Meanwhile, 1.1% of 3GC-R <italic>E. coli</italic> isolates and 2.8% of 3GC-R <italic>K. pneumoniae</italic> isolates had MICs of flomoxef of &#x02265;&#x02009;64 mg/L.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>The MIC values for cefmetazole and flomoxef against <italic>E. coli</italic> and <italic>K. pneumoniae</italic> isolated from urine and blood samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left"/><th align="left"/><th align="left" colspan="3">Cefmetazole</th><th align="left" colspan="2">Flomoxef</th></tr><tr><th align="left">Specimen</th><th align="left">Isolates</th><th align="left">Total</th><th align="left">&#x02266;16</th><th align="left">32</th><th align="left">&#x02267;64</th><th align="left">&#x02266;16</th><th align="left">32</th><th align="left">&#x02267;64</th></tr></thead><tbody><tr><td align="left" rowspan="4">Urine</td><td align="left"><italic>E. coli</italic> (all)</td><td align="left">682,034</td><td align="left">674,654 (98.9)</td><td align="left">4240 (0.6)</td><td align="left">3140 (0.5)</td><td align="left">675,602 (99.0)</td><td align="left">4476 (0.7)</td><td align="left">1956 (0.3)</td></tr><tr><td align="left">3rd Generation cephalosporin-resistant <italic>E. coli</italic></td><td align="left">164,276</td><td align="left">159,774 (97.3)</td><td align="left">2180 (1.3)</td><td align="left">2322 (1.4)</td><td align="left">160,129 (97.5)</td><td align="left">2489 (1.5)</td><td align="left">1658 (1.0)</td></tr><tr><td align="left"><italic>K. pneumoniae</italic> (all)</td><td align="left">143,842</td><td align="left">141,938 (98.7)</td><td align="left">649 (0.5)</td><td align="left">1255 (0.9)</td><td align="left">142,537 (99.1)</td><td align="left">744 (0.5)</td><td align="left">561 (0.4)</td></tr><tr><td align="left">3rd Generation cephalosporin-resistant <italic>K. pneumoniae</italic></td><td align="left">14,937</td><td align="left">13,843 (92.7)</td><td align="left">272 (1.8)</td><td align="left">822 (5.5)</td><td align="left">14,051 (94.1)</td><td align="left">439 (2.9)</td><td align="left">447 (3.0)</td></tr><tr><td align="left" rowspan="4">Blood</td><td align="left"><italic>E. coli</italic> (all)</td><td align="left">144,219</td><td align="left">142,719 (99.0)</td><td align="left">872 (0.6)</td><td align="left">628 (0.4)</td><td align="left">142,964 (99.1)</td><td align="left">853 (0.6)</td><td align="left">402 (0.3)</td></tr><tr><td align="left">3rd Generation cephalosporin-resistant <italic>E. coli</italic></td><td align="left">31,455</td><td align="left">30,516 (97.0)</td><td align="left">468 (1.5)</td><td align="left">471 (1.5)</td><td align="left">30,606 (97.3)</td><td align="left">493 (1.6)</td><td align="left">356 (1.1)</td></tr><tr><td align="left"><italic>K. pneumoniae</italic> (all)</td><td align="left">53,334</td><td align="left">52,661 (98.7)</td><td align="left">254 (0.5)</td><td align="left">419 (0.8)</td><td align="left">52,949 (99.3)</td><td align="left">247 (0.5)</td><td align="left">138 (0.2)</td></tr><tr><td align="left">3rd Generation cephalosporin-resistant <italic>K. pneumoniae</italic></td><td align="left">4053</td><td align="left">3701 (91.3)</td><td align="left">101 (2.5)</td><td align="left">251 (6.2)</td><td align="left">3797 (93.7)</td><td align="left">141 (3.5)</td><td align="left">115 (2.8)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>Interaction of cefmetazole and flomoxef with other classes of antimicrobial agents</title><p id="Par45">Next, we compared the antimicrobial drug interactions of cefmetazole and flomoxef against those of an ESBL-producing, multidrug-resistant <italic>E. coli</italic> strain. The checkerboard assay is the standard method to determine FICI as a measure of interaction between antimicrobial agents; however, the assay is labour-intensive and time-consuming. Thus, we employed the DiaMOND method, a recently developed high-throughput method to assess antimicrobial interactions in vitro (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). As shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>a, we first determined the IC<sub>50</sub> and IC<sub>90</sub> values of cefmetazole, flomoxef, and 10 other antimicrobial drugs against <italic>E. coli</italic> GU2019-E4 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). We then compared antimicrobial drug interactions of cefmetazole and flomoxef with ten different antimicrobial agents (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). We found that the two drugs showed similar antimicrobial drug interaction patterns, supporting our hypothesis that flomoxef is as active as cefmetazole, both by itself and in combination with other commonly used agents.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Antibacterial drug combination effects.&#x000a0;<bold>a</bold> Experimental and analysis workflow for measuring drug combination effects using DiaMOND method. <bold>b</bold> IC<sub>50</sub> and IC<sub>90</sub> of the antibacterial drugs against <italic>E. coli</italic> GU2019-E4 strain. CMZ, cefmetazole; FMOX, flomoxef; AMK, amikacin; MIN, minocycline; TET, tetracycline; TGC, tigecycline; AZT, aztreonam; IPM, imipenem; MEM, meropenem; FOS, fosfomycin; CST, colistin; CIP, ciprofloxacin. GEN, gentamicin; STR, streptomycin; TOB, tobramycin. <bold>c</bold> Heatmap of the combination effects of 10 antimicrobial drugs on CMZ and FMOX. Drug interactions are assessed using log2(FIC<sub>50</sub>) and log2(FIC<sub>90</sub>) values: a log2(FIC) below 0 indicates synergy (represented in blue) and a log2(FIC) above 0 indicates antagonism (represented in red)</p></caption><graphic xlink:href="12916_2025_4130_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec14"><title>Baseline characteristics of the JMDC claims database</title><p id="Par46">Between April 2014 and November 2021, 340,954 and 83,932 patients were prescribed cefmetazole and flomoxef in the JMDC database, respectively. The study comprised 4796 patients who received cefmetazole and 673 patients who received flomoxef (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). This group formed Dataset 1. Dataset 2, which excluded patients who died in the hospital from Dataset 1, comprised 4552 and 658 patients treated with cefmetazole and flomoxef, respectively. In Datasets 1 and 2, before propensity score matching, significant differences were observed between the two groups regarding age, sex, BMI, Brinkman index, Barthel index, history of diabetes, complications (sepsis, shock, respiratory failure), and underlying urinary tract abnormalities (Table <xref rid="Tab2" ref-type="table">2</xref>). Patients who received cefmetazole were more likely to be female, older, and have a history of diabetes mellitus and complications, such as sepsis, shock, and respiratory failure, compared to those who received flomoxef. Moreover, based on the JCS score, the state of consciousness was worse in the cefmetazole group than in the flomoxef group. In contrast, the flomoxef group had a higher proportion of patients with underlying urinary tract abnormalities than the cefmetazole group. After matching by propensity score, the two groups were similar with respect to baseline characteristics, except for an age.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Characteristics of the patients at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left" colspan="8">Before matching</th><th align="left" colspan="4">After matching</th></tr><tr><th align="left"/><th align="left"/><th align="left" colspan="4">Dataset 1</th><th align="left" colspan="4">Dataset 2</th><th align="left" colspan="4">Dataset 3</th></tr><tr><th align="left"/><th align="left"/><th align="left">Cefmetazole (<italic>n</italic>&#x02009;= 4796)</th><th align="left">Flomoxef (<italic>n</italic>&#x02009;= 673)</th><th align="left"><italic>P</italic> value</th><th align="left">SMD</th><th align="left">Cefmetazole (<italic>n</italic>&#x02009;= 4552)</th><th align="left">Flomoxef (<italic>n</italic>&#x02009;= 658)</th><th align="left"><italic>P</italic> value</th><th align="left">SMD</th><th align="left">Cefmetazole (<italic>n</italic>&#x02009;= 580)</th><th align="left">Flomoxef (<italic>n</italic>&#x02009;= 580)</th><th align="left"><italic>P</italic> value</th><th align="left">SMD</th></tr></thead><tbody><tr><td align="left" rowspan="2">Sex [% (<italic>N</italic>)]</td><td align="left">Female</td><td align="left">2999 (62.5)</td><td align="left">240 (35.7)</td><td align="left" rowspan="2">&#x0003c; 0.01</td><td align="left" rowspan="2">0.56</td><td align="left">2836 (62.3)</td><td align="left">231 (35.1)</td><td align="left" rowspan="2">&#x0003c; 0.01</td><td align="left" rowspan="2">0.57</td><td align="left">235 (40.5)</td><td align="left">231 (39.8)</td><td align="left" rowspan="2">0.86</td><td align="left" rowspan="2">0.01</td></tr><tr><td align="left">Male</td><td align="left">1797 (37.5)</td><td align="left">433 (64.3)</td><td align="left">1716 (37.7)</td><td align="left">427 (64.9)</td><td align="left">345 (59.5)</td><td align="left">349 (60.2)</td></tr><tr><td align="left">Age [mean (SD)]</td><td align="left"/><td align="left">78.8 (30.0)</td><td align="left">69.4 (29.6)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.32</td><td align="left">78.0 (30.2)</td><td align="left">68.9 (29.6)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.3</td><td align="left">73.4 (25.7)</td><td align="left">68.5 (31.4)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.17</td></tr><tr><td align="left" rowspan="5">BMI [% (<italic>N</italic>)]</td><td align="left">Underweight</td><td align="left">1110 (23.1)</td><td align="left">134 (19.9)</td><td align="left" rowspan="5">&#x0003c; 0.01</td><td align="left" rowspan="5">0.27</td><td align="left">1023 (22.5)</td><td align="left">130 (19.8)</td><td align="left" rowspan="5">&#x0003c; 0.01</td><td align="left" rowspan="5">0.27</td><td align="left">101 (17.4)</td><td align="left">128 (22.1)</td><td align="left" rowspan="5">0.16</td><td align="left" rowspan="5">0.15</td></tr><tr><td align="left">Normal</td><td align="left">2311 (48.2)</td><td align="left">365 (54.2)</td><td align="left">2219 (48.7)</td><td align="left">359 (54.6)</td><td align="left">319 (55.0)</td><td align="left">301 (51.9)</td></tr><tr><td align="left">Overweight</td><td align="left">607 (12.7)</td><td align="left">113 (16.8)</td><td align="left">598 (13.1)</td><td align="left">112 (17.0)</td><td align="left">111 (19.1)</td><td align="left">96 (16.6)</td></tr><tr><td align="left">Obese</td><td align="left">191 (4.0)</td><td align="left">24 (3.6)</td><td align="left">186 (4.1)</td><td align="left">24 (3.6)</td><td align="left">14 (2.4)</td><td align="left">22 (3.8)</td></tr><tr><td align="left">NA</td><td align="left">577 (12.0)</td><td align="left">37 (5.5)</td><td align="left">526 (11.6)</td><td align="left">33 (5.0)</td><td align="left">35 (6.0)</td><td align="left">33 (5.7)</td></tr><tr><td align="left" rowspan="6">Brinkman index [% (<italic>N</italic>)]</td><td align="left">0</td><td align="left">3528 (73.6)</td><td align="left">419 (62.3)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.51</td><td align="left">3339 (73.4)</td><td align="left">407 (61.9)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.51</td><td align="left">355 (61.2)</td><td align="left">389 (67.1)</td><td align="left">0.18</td><td align="left">0.15</td></tr><tr><td align="left">0&#x02013;400</td><td align="left">247 (5.2)</td><td align="left">76 (11.3)</td><td align="left"/><td align="left"/><td align="left">239 (5.3)</td><td align="left">76 (11.6)</td><td align="left"/><td align="left"/><td align="left">72 (12.4)</td><td align="left">65 (11.2)</td><td align="left"/><td align="left"/></tr><tr><td align="left">400&#x02013;800</td><td align="left">219 (4.6)</td><td align="left">72 (10.7)</td><td align="left"/><td align="left"/><td align="left">214 (4.7)</td><td align="left">71 (10.8)</td><td align="left"/><td align="left"/><td align="left">56 (9.7)</td><td align="left">52 (9.0)</td><td align="left"/><td align="left"/></tr><tr><td align="left">800&#x02013;1200</td><td align="left">114 (2.4)</td><td align="left">59 (8.8)</td><td align="left"/><td align="left"/><td align="left">111 (2.4)</td><td align="left">59 (9.0)</td><td align="left"/><td align="left"/><td align="left">46 (7.9)</td><td align="left">29 (5.0)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;&#x0003e; 1200</td><td align="left">671 (14.0)</td><td align="left">47 (7.0)</td><td align="left"/><td align="left"/><td align="left">633 (13.9)</td><td align="left">45 (6.8)</td><td align="left"/><td align="left"/><td align="left">51 (8.8)</td><td align="left">45 (7.8)</td><td align="left"/><td align="left"/></tr><tr><td align="left">NA</td><td align="left">17 (0.4)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left"/><td align="left">16 (0.4)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left"/><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Charlson comorbidity index [mean (SD)]</td><td align="left"/><td align="left">2.2 (2.5)</td><td align="left">1.7 (2.1)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.20</td><td align="left">2.1 (2.4)</td><td align="left">1.7 (2.1)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.17</td><td align="left">1.8 (2.3)</td><td align="left">1.8 (2.2)</td><td align="left">0.77</td><td align="left">0.02</td></tr><tr><td align="left">Barthel index [mean (SD)]</td><td align="left"/><td align="left">39.1 (42.6)</td><td align="left">63.8 (44.4)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.57</td><td align="left">40.6 (42.8)</td><td align="left">65.0 (44.1)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.56</td><td align="left">60.3 (43.1)</td><td align="left">60.5 (45.0)</td><td align="left">0.93</td><td align="left">&#x02009;&#x0003c; 0.01</td></tr><tr><td align="left">Diabetes [% (<italic>N</italic>)]</td><td align="left"/><td align="left">1257 (26.2)</td><td align="left">107 (15.9)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.25</td><td align="left">1177 (25.9)</td><td align="left">102 (15.5)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.26</td><td align="left">121 (20.9)</td><td align="left">98 (16.9)</td><td align="left">0.10</td><td align="left">0.10</td></tr><tr><td align="left">Sepsis [% (<italic>N</italic>)]</td><td align="left"/><td align="left">384 (8.0)</td><td align="left">24 (3.6)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.19</td><td align="left">346 (7.6)</td><td align="left">20 (3.0)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.2</td><td align="left">33 (5.7)</td><td align="left">20 (3.4)</td><td align="left">0.09</td><td align="left">0.11</td></tr><tr><td align="left">Shock [% (<bold><italic>N</italic></bold>)]</td><td align="left"/><td align="left">53 (1.1)</td><td align="left">4 (0.6)</td><td align="left">0.31</td><td align="left">0.06</td><td align="left">42 (0.9)</td><td align="left">2 (0.3)</td><td align="left">0.16</td><td align="left">0.08</td><td align="left">7 (1.2)</td><td align="left">2 (0.3)</td><td align="left">0.18</td><td align="left">0.10</td></tr><tr><td align="left">Respiratory failure [% (<bold><italic>N</italic></bold>)]</td><td align="left"/><td align="left">389 (8.1)</td><td align="left">20 (3.0)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.23</td><td align="left">328 (7.2)</td><td align="left">17 (2.6)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.22</td><td align="left">29 (5.0)</td><td align="left">17 (2.9)</td><td align="left">0.10</td><td align="left">0.11</td></tr><tr><td align="left">Acute prostatitis [% (<italic>N</italic>)]</td><td align="left"/><td align="left">42 (0.9)</td><td align="left">6 (0.9)</td><td align="left">1</td><td align="left">&#x0003c; 0.01</td><td align="left">42 (0.9)</td><td align="left">6 (0.9)</td><td align="left">1</td><td align="left">&#x0003c; 0.01</td><td align="left">3 (0.5)</td><td align="left">6 (1.0)</td><td align="left">0.50</td><td align="left">0.06</td></tr><tr><td align="left">Acute tubule-interstitial nephritis [% (<italic>N</italic>)]</td><td align="left"/><td align="left">373 (7.8)</td><td align="left">18 (2.7)</td><td align="left">&#x02009;&#x0003c; 0.01</td><td align="left">0.23</td><td align="left">359 (7.9)</td><td align="left">17 (2.6)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.24</td><td align="left">19 (3.3)</td><td align="left">17 (2.9)</td><td align="left">0.87</td><td align="left">0.02</td></tr><tr><td align="left">Cystitis [% (<italic>N</italic>)]</td><td align="left"/><td align="left">86 (1.8)</td><td align="left">12 (1.8)</td><td align="left">1</td><td align="left">&#x0003c; 0.01</td><td align="left">80 (1.8)</td><td align="left">12 (1.8)</td><td align="left">1</td><td align="left">&#x0003c; 0.01</td><td align="left">17 (2.9)</td><td align="left">11 (1.9)</td><td align="left">0.34</td><td align="left">0.07</td></tr><tr><td align="left">urinary tract disease [% (<bold><italic>N</italic></bold>)]</td><td align="left"/><td align="left">948 (19.8)</td><td align="left">321 (47.7)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.62</td><td align="left">897 (19.7)</td><td align="left">317 (48.2)</td><td align="left">&#x0003c; 0.01</td><td align="left">0.63</td><td align="left">257 (44.3)</td><td align="left">239 (41.2)</td><td align="left">0.31</td><td align="left">0.06</td></tr><tr><td align="left" rowspan="5">JCS [% (<bold><italic>N</italic></bold>)]</td><td align="left">0</td><td align="left">3420 (71.3)</td><td align="left">592 (88.0)</td><td align="left" rowspan="4">&#x0003c; 0.01</td><td align="left" rowspan="4">0.43</td><td align="left">3298 (72.5)</td><td align="left">585 (88.9)</td><td align="left" rowspan="4">&#x0003c; 0.01</td><td align="left" rowspan="4">0.43</td><td align="left">479 (82.6)</td><td align="left">507 (87.4)</td><td align="left" rowspan="4">0.13</td><td align="left" rowspan="4">0.14</td></tr><tr><td align="left">I</td><td align="left">1006 (21.0)</td><td align="left">65 (9.7)</td><td align="left">938 (20.6)</td><td align="left">60 (9.1)</td><td align="left">79 (13.6)</td><td align="left">60 (10.3)</td></tr><tr><td align="left">II</td><td align="left">273 (5.7)</td><td align="left">13 (1.9)</td><td align="left">235 (5.2)</td><td align="left">11 (1.7)</td><td align="left">19 (3.3)</td><td align="left">11 (1.9)</td></tr><tr><td align="left">III</td><td align="left">91 (1.9)</td><td align="left">3 (0.4)</td><td align="left">76 (1.7)</td><td align="left">2 (0.3)</td><td align="left">3 (0.5)</td><td align="left">2 (0.3)</td></tr><tr><td align="left">NA</td><td align="left">6 (0.1)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left"/><td align="left">5 (0.1)</td><td align="left">0 (0.0)</td><td align="left"/><td align="left"/><td align="left">0.0 (0)</td><td align="left">0.0 (0)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Mechanical ventilation</td><td align="left"/><td align="left">12 (0.3)</td><td align="left">2 (0.3)</td><td align="left">1</td><td align="left">0.01</td><td align="left">11 (0.2)</td><td align="left">2 (0.3)</td><td align="left">1</td><td align="left">0.01</td><td align="left">1 (0.2)</td><td align="left">2 (0.3)</td><td align="left">1.00</td><td align="left">0.03</td></tr><tr><td align="left">Dialysis</td><td align="left"/><td align="left">13 (0.3)</td><td align="left">3 (0.4)</td><td align="left">0.69</td><td align="left">0.03</td><td align="left">13 (0.3)</td><td align="left">3 (0.5)</td><td align="left">0.72</td><td align="left">0.03</td><td align="left">2 (0.3)</td><td align="left">3 (0.5)</td><td align="left">1.00</td><td align="left">0.03</td></tr><tr><td align="left">Vasopressor use</td><td align="left"/><td align="left">64 (1.3)</td><td align="left">4 (0.6)</td><td align="left">0.15</td><td align="left">0.08</td><td align="left">60 (1.3)</td><td align="left">3 (0.5)</td><td align="left">0.09</td><td align="left">0.09</td><td align="left">4 (0.7)</td><td align="left">3 (0.5)</td><td align="left">1.00</td><td align="left">0.02</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>BMI</italic> body mass index, <italic>JCS</italic> Japan Coma Scale, <italic>SD</italic> standard deviation, <italic>SMD</italic> standardized mean difference </p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Patient flowchart in the claim data analysis. Flow diagram of patient inclusion and set up of each dataset. Abbreviations: DPC, Diagnosis Procedure Combination</p></caption><graphic xlink:href="12916_2025_4130_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec15"><title>Primary effectiveness outcome</title><p id="Par47">Dataset 2 was used to compare the two groups in terms of days to hospital discharge. The median time to discharge was 11 days (95% confidence interval [CI] 11&#x02013;11) in the cefmetazole group and 4 days (95% CI: 3&#x02013;5) in the flomoxef group, with significantly fewer days in the flomoxef group (log-rank test: <italic>P</italic>&#x02009;&#x0003c; 0.001) (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Cox-proportional hazards analysis also revealed an HR of 1.70 (95% CI 1.56&#x02013;1.85, <italic>P</italic>&#x02009;&#x0003c; 0.001) for live discharge in the flomoxef group.
<fig id="Fig4"><label>Fig. 4</label><caption><p>Kaplan&#x02013;Meier plot illustrating survival post-discharge in Dataset 2. Kaplan-Meier curves for length of hospital stay by antimicrobial agent. Kaplan-Meier plots show hospitalization rates for patients in the cefmetazole and flomoxef groups from index date to survival discharge for Dataset 2</p></caption><graphic xlink:href="12916_2025_4130_Fig4_HTML" id="MO4"/></fig></p><p id="Par48">The duration of hospital stay until discharge was evaluated using Dataset 3, following propensity score matching. In this analysis, the median time to discharge was 9 days (95% CI 8&#x02013;10) for patients in the cefmetazole group, compared to 5 days (95% CI 4&#x02013;6) for those in the flomoxef group. Thus, the flomoxef group experienced significantly shorter hospital stays, as evidenced even after propensity score matching (log-rank test: <italic>P</italic>&#x02009;&#x0003c; 0.001) (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). The hazard ratio for live discharge associated with flomoxef use was 1.60 (95% CI 1.42&#x02013;1.81, <italic>P</italic>&#x02009;&#x0003c; 0.001). In the sensitivity analysis conducted using the IPW method, the hazard ratio for survival to discharge associated with flomoxef was 1.41 (95% CI 1.25&#x02013;1.58; <italic>P</italic>&#x02009;= 0.001).
<fig id="Fig5"><label>Fig. 5</label><caption><p>Kaplan&#x02013;Meier plot illustrating survival post-discharge in Dataset 3. Kaplan&#x02013;Meier curves for the length of hospital stay by an antimicrobial agent. Kaplan&#x02013;Meier plots show hospitalization rates for patients in the cefmetazole and flomoxef groups from index date to survival discharge for Dataset 3</p></caption><graphic xlink:href="12916_2025_4130_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec16"><title>Secondary effectiveness outcome</title><p id="Par49">The 28-day mortality rate was 2.71% (130/4796) in the cefmetazole group and 1.34% (9/673) in the flomoxef group, and multiple logistic regression analysis showed no significant difference between the two groups (OR 1.08, 95% CI 0.53&#x02013;2.21, <italic>P</italic>&#x02009;= 0.836). Prescriptions for carbapenems were ordered for 6.01% (288/4796) and 4.61% (31/673) in the cefmetazole and flomoxef groups, respectively (OR 1.05, 95% CI 0.70&#x02013;1.57, <italic>P</italic>&#x02009;= 0.824) (Table <xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Secondary efficacy endpoints</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Odds ratio (flomoxef/cefmetazole)</th><th align="left">95% CI</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">28-day mortality</td><td align="left">1.08</td><td align="left">0.53&#x02013;2.21</td><td align="left">0.836</td></tr><tr><td align="left">Carbapenem use</td><td align="left">1.05</td><td align="left">0.70&#x02013;1.57</td><td align="left">0.824</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>CI</italic> confidence interval</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec17"><title>Safety outcome</title><p id="Par50">The incidences of AEs related to the gastrointestinal, renal, and hepatic systems and hypersensitivity reactions were analysed (Table <xref rid="Tab4" ref-type="table">4</xref>). Renal failure was the most reported AE in the cefmetazole group, affecting 7.5% of patients. This was followed by hepatic dysfunction, occurring in 2.3% of the cases. Furthermore, gastrointestinal AEs included <italic>C. difficile</italic> infection in 1.1% of the patients in the cefmetazole group. In the flomoxef group, renal failure (3.6%) was also the most common adverse event, followed by hepatic dysfunction (2.5%) and other forms of kidney dysfunction (0.9%). <italic>C. difficile</italic> infection (<italic>P</italic>&#x02009;= 0.03) and kidney failure (<italic>P</italic>&#x02009;= 0.04) were significantly less common in the flomoxef group than in the cefmetazole group. In the safety analysis of Dataset 3, similar to the findings in Dataset 1, the cefmetazole group showed a significantly higher incidence of kidney failure compared to the flomoxef group (<italic>P</italic>&#x02009;&#x0003c; 0.01) (Additional File 6).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Safety endpoints of Dataset 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Cefmetazole (<italic>n</italic>&#x02009;= 4796)</th><th align="left">Flomoxef (<italic>n</italic>&#x02009;= 673)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="4">Gastrointestinal</td></tr><tr><td align="left">&#x02003;Non-<italic>C. difficile</italic> diarrhoea [% (<italic>N</italic>)]</td><td align="left">23 (0.5)</td><td align="left">0 (0.0)</td><td align="left">0.14</td></tr><tr><td align="left"><italic>&#x02003;C. difficile</italic> infection [% (<italic>N</italic>)]</td><td align="left">4 (0.1)</td><td align="left">0 (0.0)</td><td align="left">1</td></tr><tr><td align="left" colspan="4">Kidney</td></tr><tr><td align="left">&#x02003;Kidney failure [% (<italic>N</italic>)]</td><td align="left">360 (7.5)</td><td align="left">24 (3.6)</td><td align="left">&#x0003c; 0.01</td></tr><tr><td align="left">&#x02003;Other kidney dysfunction [% (<italic>N</italic>)]</td><td align="left">54 (1.1)</td><td align="left">6 (0.9)</td><td align="left">0.73</td></tr><tr><td align="left" colspan="4">Liver</td></tr><tr><td align="left">&#x02003;Liver dysfunction [% (<italic>N</italic>)]</td><td align="left">108 (2.3)</td><td align="left">17 (2.5)</td><td align="left">0.76</td></tr><tr><td align="left" colspan="4">Hypersensitivity</td></tr><tr><td align="left">&#x02003;Anaphylactic shock [% (<italic>N</italic>)]</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left">NA</td></tr><tr><td align="left">&#x02003;Rash [% (<italic>N</italic>)]</td><td align="left">2 (0.0)</td><td align="left">0 (0.0)</td><td align="left">1</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par51">This study investigated the effectiveness and safety of flomoxef compared with cefmetazole in patients with UTIs. Our analysis of the Japanese surveillance data showed that the in vitro resistance rates of third-generation cephalosporin-resistant <italic>E. coli</italic> and <italic>K. pneumoniae</italic> for flomoxef were lower than those for cefmetazole. The in vitro evaluation of the combined antimicrobial activities against an ESBL-producing multidrug-resistant strain demonstrated that both drugs exhibited similar patterns of interaction. An analysis of the claims data revealed that the length of hospital stay for patients with UTIs requiring treatment was shorter in the flomoxef group than in the cefmetazole group, with no significant difference in 28-day mortality or the rate of additional carbapenem prescriptions. The incidence rates of <italic>C. difficile</italic> infection and renal failure after therapy were significantly lower in the flomoxef group than in the cefmetazole group. Considering these data, flomoxef may be a potential treatment option for UTIs, including those caused by ESBL-producing bacteria, in clinical practice.</p><p id="Par52">Cefmetazole and flomoxef both possess a structure containing a 7-&#x003b1;-methoxy group. This structural feature hinders access to the active site of enzymes through steric hindrance [<xref ref-type="bibr" rid="CR28">28</xref>]. As a result, hydrolysis by &#x003b2;-lactamases is reduced, enabling these agents to exhibit efficacy against ESBL-producing bacteria. Indeed, treatment with cefmetazole or flomoxef may serve as an effective alternative to carbapenem therapy for bloodstream infections caused by ESBL-producing <italic>Escherichia coli</italic> [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par53">To date, no adequately powered randomized controlled trials have compared the relative efficacy of cephamycin and oxacephem against infections due to ESBL-producing bacteria. Several observational studies have compared the effectiveness of a cephamycin or an oxacephem, but all had relatively small numbers of patients [<xref ref-type="bibr" rid="CR30">30</xref>]. As a result, clinical data on the use of a cephamycin or an oxacephem for bacteria, including ESBL-producing bacteria, are scarce, and the difference in efficacy between cefmetazole and flomoxef is unknown.</p><p id="Par54">The CLSI defines the MIC breakpoints for cefmetazole against <italic>Enterobacterales</italic> as &#x02264;&#x02009;16 &#x003bc;g/mL: Susceptible, 32 &#x003bc;g/mL: Intermediate, and &#x02265;&#x02009;64 &#x003bc;g/mL Resistant [<xref ref-type="bibr" rid="CR31">31</xref>]. The JANIS data showed that flomoxef tended to have a lower frequency of MIC &#x02265;&#x02009;64 &#x003bc;g/mL against 3GC-R <italic>E. coli</italic> and <italic>K. pneumoniae</italic>, including ESBL-producing bacteria, compared to cefmetazole. Indeed, a previous study reported lower MIC<sub>90</sub> values of flomoxef than those of cefmetazole against ESBL-producing <italic>E. coli</italic> and <italic>K. pneumonia</italic> [<xref ref-type="bibr" rid="CR32">32</xref>]. These data suggest that flomoxef may be considered a viable treatment option for ESBL-producing bacteria. In addition, the findings from the DiaMOND assay support the hypothesis that flomoxef is as effective as cefmetazole, not only as a standalone treatment but also when combined with other drugs. This is important for clinical practice, as it provides flexibility in treatment strategies, especially in regions with high prevalence rates of ESBL-producing bacteria.</p><p id="Par55">The JMDC claims database used in this study encompasses data from 860 facilities across Japan, which are deemed representative of routine medical practices [<xref ref-type="bibr" rid="CR33">33</xref>]. A previous study showed that over 80% of UTIs were attributed to either <italic>E. coli</italic> or <italic>K. pneumoniae</italic> [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], and this epidemiological information can be extrapolated to the JMDC claim data as well. In addition, antimicrobial susceptibility testing results for clinical isolates during the same period as the claim data analysis may reflect the resistance status in the clinical background of the claims data. Therefore, part of the effectiveness of flomoxef observed in the claims data analysis may be explained by the difference in the rate of resistance between cefmetazole and flomoxef.</p><p id="Par56">This study has several limitations. First, biases might exist in the clinical decision-making regarding the choice between cefmetazole and flomoxef. While there is no definitive evidence favouring the effectiveness of cefmetazole over flomoxef, it was observed that in claim data used in the present study, cefmetazole was more frequently prescribed to patients in a more severe general condition. Second, the claims data used in this study were limited to the hospitalization of interest, and any AEs occurring after discharge from the hospital were not captured. The median length of hospital stay for flomoxef was approximately half that for cefmetazole, which may have resulted in a shorter observation period for AEs in the flomoxef group. Third, the ICD-10 codes include numerous conditions beyond N39 that suggest urinary tract infections, and relying solely on N39 may unnecessarily exclude cases of urinary tract infections. For instance, acute interstitial nephritis (ICD-10 code: N10) is also a condition that suggests urinary tract infections. However, these conditions can have multiple causes other than infections [<xref ref-type="bibr" rid="CR36">36</xref>]. Limiting the infections that prompted the administration of cefmetazole and flomoxef to specific conditions helps homogenize the patient backgrounds in both groups and enhances comparability. Therefore, this study used only the ICD-10 code N39. Fourth, this study lacked the use of confirmatory diagnostic methods, such as CTX-M gene analysis, double-disk synergy test (DDST), ESBL/AmpC confirmation tests, and modified carbapenem inactivation method (mCIM). This prevents definitive identification of ESBL-producing strains, resulting in the possibility of coexisting AmpC &#x003b2;-lactamases or unresolved OXA-type &#x003b2;-lactamases. These factors may have introduced potential bias in evaluating the individual and combined effects of cefmetazole and flomoxef, necessitating careful consideration in data interpretation.</p><p id="Par57">Flomoxef lacks sufficient pharmacological data in humans, and the CLSI breakpoint for flomoxef has not yet been defined. Despite increasing international attention on flomoxef, including its use in Global Antibiotic Research &#x00026; Development Partnership (GARDP) clinical studies, information on its clinical efficacy remains limited [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. This study demonstrates that flomoxef can be a viable treatment option for UTIs comparable to cefmetazole, utilising national claim data and antimicrobial resistance surveillance data. Considering the recent shortage of critical antimicrobials, particularly &#x003b2;-lactam antimicrobials, in clinical settings, flomoxef is expected to be considered as a potential option against ESBL-producing bacteria, similar to cefmetazole and carbapenem antimicrobials [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. We acknowledge the importance of cost considerations in antimicrobial stewardship programs. While the brand-name drug price of flomoxef is higher than that of cefmetazole, the patent for flomoxef has expired [<xref ref-type="bibr" rid="CR38">38</xref>]. With the accumulation of data from studies, such as ours, the utilisation of flomoxef, including its generic versions, will become more widespread.</p></sec><sec id="Sec19"><title>Conclusions</title><p id="Par58">The effectiveness of flomoxef may be comparable to that of cefmetazole in treating UTIs without major complications. Thus, flomoxef is a viable treatment option for UTIs in locales with a high prevalence of ESBL-producing strains. To further elucidate the therapeutic value of flomoxef as a treatment option, more comprehensive evaluations of its clinical efficacy are warranted, particularly focusing on its potential effectiveness against drug-resistant pathogens. This assessment should involve rigorous clinical studies to establish its comparative advantages in antimicrobial stewardship programs and infection control strategies.</p></sec><sec id="Sec24" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4130_MOESM1_ESM.docx"><caption><p>Additional file 1. Definition of UTI.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4130_MOESM2_ESM.docx"><caption><p>Additional file 2. Definition of complicating disease.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12916_2025_4130_MOESM3_ESM.docx"><caption><p>Additional file 3. Definition of medical history.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12916_2025_4130_MOESM4_ESM.docx"><caption><p>Additional file 4. Definition of safety outcomes adverse events.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12916_2025_4130_MOESM5_ESM.docx"><caption><p>Additional file 5. The MIC distribution.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="12916_2025_4130_MOESM6_ESM.docx"><caption><p>Additional file 6. Safety endpoints of Dataset 3.</p></caption></media></supplementary-material></p></sec></body><back><glossary id="AGS1"><title>Abbreviations</title><def-list><def-item><term>ADL</term><def><p id="Par5">Activities of Daily Living</p></def></def-item><def-item><term>AE</term><def><p id="Par6">Adverse event</p></def></def-item><def-item><term>AMED</term><def><p id="Par7">Japan Agency for Medical Research and Development</p></def></def-item><def-item><term>BMI</term><def><p id="Par8">Body mass index</p></def></def-item><def-item><term>CI</term><def><p id="Par9">Confidence Interval</p></def></def-item><def-item><term>CLSI</term><def><p id="Par10">Clinical and Laboratory Standards Institute</p></def></def-item><def-item><term><italic>C. difficile</italic></term><def><p id="Par11">
<italic>Clostridioides difficile</italic>
</p></def></def-item><def-item><term>DPC</term><def><p id="Par12">Diagnosis Procedure Combination</p></def></def-item><def-item><term>ESBL</term><def><p id="Par13">Extended-Spectrum Beta-Lactamase</p></def></def-item><def-item><term>FICI</term><def><p id="Par14">Fractional inhibitory concentration index</p></def></def-item><def-item><term>IC90</term><def><p id="Par15"> 90% Inhibitory concentration</p></def></def-item><def-item><term>ICD-10</term><def><p id="Par16">International Statistical Classification of Diseases and Related Health Problems, 10th Revision</p></def></def-item><def-item><term>JANIS</term><def><p id="Par17">Japan Nosocomial Infections Surveillance</p></def></def-item><def-item><term>JMDC</term><def><p id="Par18">Japan Medical Data Center</p></def></def-item><def-item><term>JCS</term><def><p id="Par19">Japan Coma Scale</p></def></def-item><def-item><term>MIC</term><def><p id="Par20">Minimum inhibitory concentration</p></def></def-item><def-item><term>OR</term><def><p id="Par21"> Odds ratio</p></def></def-item><def-item><term>UPEC</term><def><p id="Par22">Uropathogenic <italic>Escherichia coli</italic></p></def></def-item><def-item><term>UTI</term><def><p id="Par23">Urinary tract infection</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Takahiro Niimura and Mitsuhiro Goda these authors contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Dr. Yohei Doi for the critical reading of the manuscript. We thank Dr. Kevin Laupland for supporting the research project and reading the manuscript. We are grateful to all the hospitals that participated in and contributed data to the JANIS. We thank Dr. Masami Murakami for providing the <italic>E. coli</italic> clinical strain UPEC GU2019-E4.</p></ack><notes notes-type="author-contribution"><title>Authors' contributions</title><p>Data collection, Analysis, Interpretation, and Statistical analysis: TN, TK, KY, KM, YM, MI, MS1. Drafting manuscript: TN, TK, YM. Manuscript revision: TN, MG, SN, TK, KY, AH, YM, MS2, KI. All the authors have read and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Japan Agency for Medical Research and Development (AMED) [grant number JP23wm0325037, JP24fk0108665, JP24fk0108683, JP24fk0108712, JP24fk0108642, JP24gm1610003, JP24wm0225029, JP24wm0225022, and JP23 gm1610013] and JSPS KAKENHI Grant (23H02634, 23K27325), and Health Labour Sciences Research Grant, Ministry of Health, Labour and Welfare (25HA1004).&#x000a0;The funders had no role in the study design; collection, analysis, and interpretation of data; writing of the report; or decision to submit for publication.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data will be made available upon request from the corresponding author after the approval of the proposal.
</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par59">This part of the study was approved by the Ethics Committee of Tokushima University Hospital (protocol number: 4492).</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par60">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par61">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Livermore</surname><given-names>DM</given-names></name><name><surname>Canton</surname><given-names>R</given-names></name><name><surname>Gniadkowski</surname><given-names>M</given-names></name><name><surname>Nordmann</surname><given-names>P</given-names></name><name><surname>Rossolini</surname><given-names>GM</given-names></name><name><surname>Arlet</surname><given-names>G</given-names></name><etal/></person-group><article-title>CTX-M: changing the face of ESBLs in Europe</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>59</volume><issue>2</issue><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl483</pub-id><?supplied-pmid 17158117?><pub-id pub-id-type="pmid">17158117</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59(2):165&#x02013;74. 10.1093/jac/dkl483.<pub-id pub-id-type="pmid">17158117</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J: A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group. Antimicrob Agents Chemother. 2000;44(11):3177&#x02013;79. 10.1128/AAC.44.11.3177-3179.2000. Pubmed: 11036046.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Tumbarello</surname><given-names>M</given-names></name><name><surname>Spanu</surname><given-names>T</given-names></name><name><surname>Sanguinetti</surname><given-names>M</given-names></name><name><surname>Citton</surname><given-names>R</given-names></name><name><surname>Montuori</surname><given-names>E</given-names></name><name><surname>Leone</surname><given-names>F</given-names></name><etal/></person-group><article-title>Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome</article-title><source>Antimicrob Agents Chemother</source><year>2006</year><volume>50</volume><issue>2</issue><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1128/AAC.50.2.498-504.2006</pub-id><?supplied-pmid 16436702?><pub-id pub-id-type="pmid">16436702</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006;50(2):498&#x02013;504. 10.1128/AAC.50.2.498-504.2006.<pub-id pub-id-type="pmid">16436702</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Limbago</surname><given-names>BM</given-names></name><name><surname>Patel</surname><given-names>JB</given-names></name><name><surname>Kallen</surname><given-names>AJ</given-names></name></person-group><article-title>Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention</article-title><source>Clin Infect Dis</source><year>2011</year><volume>53</volume><issue>1</issue><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1093/cid/cir202</pub-id><?supplied-pmid 21653305?><pub-id pub-id-type="pmid">21653305</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1):60&#x02013;7. 10.1093/cid/cir202. Pubmed:21653305.<pub-id pub-id-type="pmid">21653305</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Schentag</surname><given-names>JJ</given-names></name></person-group><article-title>Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials</article-title><source>Pharmacotherapy</source><year>1991</year><volume>11</volume><issue>1</issue><fpage>2</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1002/j.1875-9114.1991.tb03592.x</pub-id><?supplied-pmid 2020609?><pub-id pub-id-type="pmid">2020609</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Schentag JJ. Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials. Pharmacotherapy. 1991;11(1):2&#x02013;19. 10.1002/j.1875-9114.1991.tb03592.x. Pubmed:2020609.<pub-id pub-id-type="pmid">2020609</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>H</given-names></name><name><surname>Narisada</surname><given-names>M</given-names></name><name><surname>Hamashima</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name></person-group><article-title>Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic</article-title><source>J Antibiot (Tokyo)</source><year>1985</year><volume>38</volume><issue>4</issue><fpage>466</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.38.466</pub-id><?supplied-pmid 4008339?><pub-id pub-id-type="pmid">4008339</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Tsuji T, Satoh H, Narisada M, Hamashima Y, Yoshida T. Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic. J Antibiot (Tokyo). 1985;38(4):466&#x02013;76. 10.7164/antibiotics.38.466. Pubmed:4008339.<pub-id pub-id-type="pmid">4008339</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Ishigami</surname><given-names>T</given-names></name></person-group><article-title>The meaning of the development of flomoxef and clinical experience in Japan</article-title><source>Infection</source><year>1991</year><volume>19</volume><issue>Suppl 5</issue><fpage>S253</fpage><lpage>S257</lpage><pub-id pub-id-type="doi">10.1007/BF01645536</pub-id><?supplied-pmid 1783441?><pub-id pub-id-type="pmid">1783441</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ito M, Ishigami T. The meaning of the development of flomoxef and clinical experience in Japan. Infection. 1991;19(Suppl 5):S253&#x02013;7. 10.1007/BF01645536. Pubmed:1783441.<pub-id pub-id-type="pmid">1783441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">World Health Organization. Application for the inclusion of flomoxef sodium on the WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc). Geneva: World Health Organization; 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://cdn.who.int/media/docs/default-source/essential-medicines/2023-eml-expert-committee/applications-for-addition-of-new-medicines/a17_flomoxef-sodium.pdf?sfvrsn=9f6f1aeb_1">https://cdn.who.int/media/docs/default-source/essential-medicines/2023-eml-expert-committee/applications-for-addition-of-new-medicines/a17_flomoxef-sodium.pdf?sfvrsn=9f6f1aeb_1</ext-link>.</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Bonomo</surname><given-names>RA</given-names></name></person-group><article-title>Extended-spectrum &#x003b2;-lactamases: A clinical update</article-title><source>Clin Microbiol Rev</source><year>2005</year><volume>18</volume><issue>4</issue><fpage>657</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1128/CMR.18.4.657-686.2005</pub-id><?supplied-pmid 16223952?><pub-id pub-id-type="pmid">16223952</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Paterson DL, Bonomo RA. Extended-spectrum &#x003b2;-lactamases: A clinical update. Clin Microbiol Rev. 2005;18(4):657&#x02013;86. 10.1128/CMR.18.4.657-686.2005. Pubmed:16223952.<pub-id pub-id-type="pmid">16223952</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Nagao</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Takakura</surname><given-names>S</given-names></name><name><surname>Ichiyama</surname><given-names>S</given-names></name></person-group><article-title>In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum &#x003b2;-lactamase and plasmid-mediated AmpC &#x003b2;-lactamase-producing Enterobacteriaceae</article-title><source>Diagn Microbiol Infect Dis</source><year>2016</year><volume>84</volume><issue>4</issue><fpage>322</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2015.12.001</pub-id><?supplied-pmid 26782634?><pub-id pub-id-type="pmid">26782634</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum &#x003b2;-lactamase and plasmid-mediated AmpC &#x003b2;-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016;84(4):322&#x02013;7. 10.1016/j.diagmicrobio.2015.12.001. Pubmed:26782634.<pub-id pub-id-type="pmid">26782634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><etal/></person-group><article-title>In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum &#x003b2;-lactamases in China</article-title><source>Int J Antimicrob Agents</source><year>2015</year><volume>45</volume><issue>5</issue><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.11.012</pub-id><?supplied-pmid 25600890?><pub-id pub-id-type="pmid">25600890</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yang Q, Zhang H, Cheng J, Xu Z, Xu Y, Cao B, et al. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum &#x003b2;-lactamases in China. Int J Antimicrob Agents. 2015;45(5):485&#x02013;90. 10.1016/j.ijantimicag.2014.11.012. Pubmed:25600890.<pub-id pub-id-type="pmid">25600890</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Tsuzuki</surname><given-names>S</given-names></name><name><surname>Sakurai</surname><given-names>A</given-names></name><name><surname>Tanizaki</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum &#x003b2;-lactamase-producing Escherichia coli</article-title><source>Antimicrob Agents Chemother</source><year>2023</year><volume>67</volume><issue>10</issue><fpage>e0051023</fpage><pub-id pub-id-type="doi">10.1128/aac.00510-23</pub-id><?supplied-pmid 37702483?><pub-id pub-id-type="pmid">37702483</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Hayakawa K, Matsumura Y, Uemura K, Tsuzuki S, Sakurai A, Tanizaki R, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum &#x003b2;-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2023;67(10):e0051023. 10.1128/aac.00510-23. Pubmed:37702483.<pub-id pub-id-type="pmid">37702483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Kashihara E, Sada RM, Tsugihashi Y, Obayashi H, Nakamura A, Abe N, et al. Efficacy and safety of cefmetazole for bacteremia caused by extended-spectrum &#x003b2;-lactamase-producing Enterobacterales vs carbapenems: A retrospective study. Open Forum Infect Dis. 2023;10(10):ofad502. 10.1093/ofid/ofad502.</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Iio</surname><given-names>K</given-names></name><name><surname>Hagiya</surname><given-names>H</given-names></name><name><surname>Higashionna</surname><given-names>T</given-names></name><name><surname>Otsuka</surname><given-names>F</given-names></name></person-group><article-title>In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales</article-title><source>New Microbiol</source><year>2024</year><volume>46</volume><issue>4</issue><fpage>348</fpage><lpage>353</lpage><?supplied-pmid 38252045?><pub-id pub-id-type="pmid">38252045</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Iio K, Hagiya H, Higashionna T, Otsuka F. In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales. New Microbiol. 2024;46(4):348&#x02013;53.<pub-id pub-id-type="pmid">38252045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Komatsu</surname><given-names>Y</given-names></name><name><surname>Kasahara</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><name><surname>Muratani</surname><given-names>T</given-names></name><name><surname>Yano</surname><given-names>H</given-names></name><name><surname>Kirita</surname><given-names>T</given-names></name><name><surname>Mikasa</surname><given-names>K</given-names></name></person-group><article-title>Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><issue>8</issue><fpage>e0202276</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0202276</pub-id><?supplied-pmid 30157275?><pub-id pub-id-type="pmid">30157275</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Komatsu Y, Kasahara K, Inoue T, Lee ST, Muratani T, Yano H, Kirita T, Mikasa K. Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan. PLoS ONE. 2018;13(8):e0202276. 10.1371/journal.pone.0202276.<pub-id pub-id-type="pmid">30157275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Boston Consulting Group, Wellcome Trust. Understanding the antibiotic manufacturing ecosystem: a view of global supply chains, pressure points, and implications for antimicrobial resistance response. 2022. Available from: <ext-link ext-link-type="uri" xlink:href="https://cms.wellcome.org/sites/default/files/2022-04/understanding-the-antibiotic-manufacturing-ecosystem-2022.pdf">https://cms.wellcome.org/sites/default/files/2022-04/understanding-the-antibiotic-manufacturing-ecosystem-2022.pdf</ext-link>.</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Nagano</surname><given-names>H</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Kunisawa</surname><given-names>S</given-names></name><name><surname>Fushimi</surname><given-names>K</given-names></name><name><surname>Nagao</surname><given-names>M</given-names></name><name><surname>Imanaka</surname><given-names>Y</given-names></name></person-group><article-title>Impact of the cefazolin shortage on the selection and cost of parenteral antibiotics during the supply disruption period in Japan: a controlled interrupted time series analysis</article-title><source>J Infect Public Health</source><year>2023</year><volume>16</volume><issue>3</issue><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2023.01.021</pub-id><?supplied-pmid 36738690?><pub-id pub-id-type="pmid">36738690</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Nagano H, Shin JH, Kunisawa S, Fushimi K, Nagao M, Imanaka Y. Impact of the cefazolin shortage on the selection and cost of parenteral antibiotics during the supply disruption period in Japan: a controlled interrupted time series analysis. J Infect Public Health. 2023;16(3):467&#x02013;73. 10.1016/j.jiph.2023.01.021. Pubmed:36738690.<pub-id pub-id-type="pmid">36738690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Kajihara</surname><given-names>T</given-names></name><name><surname>Yahara</surname><given-names>K</given-names></name><name><surname>Hirabayashi</surname><given-names>A</given-names></name><name><surname>Shibayama</surname><given-names>K</given-names></name><name><surname>Sugai</surname><given-names>M</given-names></name></person-group><article-title>Japan Nosocomial Infections Surveillance (JANIS): current status, international collaboration, and future directions for a comprehensive antimicrobial resistance surveillance system</article-title><source>Jpn J Infect Dis</source><year>2021</year><volume>74</volume><issue>2</issue><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.7883/yoken.JJID.2020.499</pub-id><?supplied-pmid 32863357?><pub-id pub-id-type="pmid">32863357</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kajihara T, Yahara K, Hirabayashi A, Shibayama K, Sugai M. Japan Nosocomial Infections Surveillance (JANIS): current status, international collaboration, and future directions for a comprehensive antimicrobial resistance surveillance system. Jpn J Infect Dis. 2021;74(2):87&#x02013;96. 10.7883/yoken.JJID.2020.499.<pub-id pub-id-type="pmid">32863357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Ministry of Health, Labour and Welfare. Orientation Session for the Submission and Utilization of Data in the Japan Nosocomial Infections Surveillance (JANIS) Program 2017. Tokyo: Japan Nosocomial Infections Surveillance (JANIS); 2017. Available from: <ext-link ext-link-type="uri" xlink:href="https://janis.mhlw.go.jp/participation/material/2017_janis_briefing_slide.pdf">https://janis.mhlw.go.jp/participation/material/2017_janis_briefing_slide.pdf</ext-link>.</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Cokol</surname><given-names>M</given-names></name><name><surname>Kuru</surname><given-names>N</given-names></name><name><surname>Bicak</surname><given-names>E</given-names></name><name><surname>Larkins-Ford</surname><given-names>J</given-names></name><name><surname>Aldridge</surname><given-names>BB</given-names></name></person-group><article-title>Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis</article-title><source>Sci Adv</source><year>2017</year><volume>3</volume><issue>10</issue><fpage>e1701881</fpage><pub-id pub-id-type="doi">10.1126/sciadv.1701881</pub-id><?supplied-pmid 29026882?><pub-id pub-id-type="pmid">29026882</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Cokol M, Kuru N, Bicak E, Larkins-Ford J, Aldridge BB. Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. Sci Adv. 2017;3(10):e1701881. 10.1126/sciadv.1701881. Pubmed:29026882.<pub-id pub-id-type="pmid">29026882</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>N</given-names></name><name><surname>Degefu</surname><given-names>YN</given-names></name><name><surname>Aldridge</surname><given-names>BB</given-names></name></person-group><article-title>Efficient measurement of drug interactions with DiaMOND (Diagonal Measurement of N-Way Drug Interactions)</article-title><source>Methods Mol Biol</source><year>2021</year><volume>2314</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1460-0_30</pub-id><?supplied-pmid 34235676?><pub-id pub-id-type="pmid">34235676</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Van N, Degefu YN, Aldridge BB. Efficient measurement of drug interactions with DiaMOND (Diagonal Measurement of N-Way Drug Interactions). Methods Mol Biol. 2021;2314:703&#x02013;13. 10.1007/978-1-0716-1460-0_30. Pubmed:34235676.<pub-id pub-id-type="pmid">34235676</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirakawa</surname><given-names>H</given-names></name><name><surname>Takita</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Hiramoto</surname><given-names>S</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Ohshima</surname><given-names>N</given-names></name><etal/></person-group><article-title>Inactivation of ackA and pta genes reduces GlpT expression and susceptibility to fosfomycin in Escherichia coli</article-title><source>Microbiol Spectr</source><year>2023</year><volume>11</volume><issue>3</issue><fpage>e0506922</fpage><pub-id pub-id-type="doi">10.1128/spectrum.05069-22</pub-id><?supplied-pmid 37199605?><pub-id pub-id-type="pmid">37199605</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Hirakawa H, Takita A, Sato Y, Hiramoto S, Hashimoto Y, Ohshima N, et al. Inactivation of ackA and pta genes reduces GlpT expression and susceptibility to fosfomycin in Escherichia coli. Microbiol Spectr. 2023;11(3):e0506922. 10.1128/spectrum.05069-22. Pubmed:37199605.<pub-id pub-id-type="pmid">37199605</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Yasunaga H. In: Real world data in Japan: Chapter II. The diagnosis procedure combination database. Ann Clin Epidemiol. 2019;1:76&#x02013;9.</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Shiozawa</surname><given-names>M</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name><name><surname>Morita</surname><given-names>K</given-names></name><name><surname>Okada</surname><given-names>A</given-names></name><name><surname>Matsuoka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association of body mass index with ischemic and hemorrhagic stroke</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><issue>7</issue><fpage>2343</fpage><pub-id pub-id-type="doi">10.3390/nu13072343</pub-id><?supplied-pmid 34371853?><pub-id pub-id-type="pmid">34371853</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Shiozawa M, Kaneko H, Itoh H, Morita K, Okada A, Matsuoka S, et al. Association of body mass index with ischemic and hemorrhagic stroke. Nutrients. 2021;13(7):2343. 10.3390/nu13072343. Pubmed:34371853.<pub-id pub-id-type="pmid">34371853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Shigematsu</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name></person-group><article-title>The eye response test alone is sufficient to predict stroke outcome&#x02014;reintroduction of Japan Coma Scale: a cohort study</article-title><source>BMJ Open</source><year>2013</year><volume>3</volume><issue>4</issue><fpage>e002736</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2013-002736</pub-id><?supplied-pmid 23633419?><pub-id pub-id-type="pmid">23633419</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict stroke outcome&#x02014;reintroduction of Japan Coma Scale: a cohort study. BMJ Open. 2013;3(4):e002736. 10.1136/bmjopen-2013-002736. Pubmed:23633419.<pub-id pub-id-type="pmid">23633419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Sonoo</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name></person-group><article-title>Development and validation of a novel method for converting the Japan Coma Scale to Glasgow Coma Scale</article-title><source>J Epidemiol</source><year>2023</year><volume>33</volume><issue>10</issue><fpage>531</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.2188/jea.JE20220147</pub-id><?supplied-pmid 35851565?><pub-id pub-id-type="pmid">35851565</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Nakajima M, Okada Y, Sonoo T, Goto T. Development and validation of a novel method for converting the Japan Coma Scale to Glasgow Coma Scale. J Epidemiol. 2023;33(10):531&#x02013;5. 10.2188/jea.JE20220147. Pubmed:35851565.<pub-id pub-id-type="pmid">35851565</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>H</given-names></name><name><surname>Sundararajan</surname><given-names>V</given-names></name><name><surname>Halfon</surname><given-names>P</given-names></name><name><surname>Fong</surname><given-names>A</given-names></name><name><surname>Burnand</surname><given-names>B</given-names></name><name><surname>Luthi</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data</article-title><source>Med Care</source><year>2005</year><volume>43</volume><issue>11</issue><fpage>1130</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1097/01.mlr.0000182534.19832.83</pub-id><?supplied-pmid 16224307?><pub-id pub-id-type="pmid">16224307</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130&#x02013;9. 10.1097/01.mlr.0000182534.19832.83. Pubmed:16224307.<pub-id pub-id-type="pmid">16224307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Wi</surname><given-names>YM</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>DE</given-names></name><name><surname>Jun</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>KT</given-names></name><name><surname>Ko</surname><given-names>KS</given-names></name></person-group><article-title>Antimicrobial activity of cephamycins and &#x003b2;-lactam/&#x003b2;-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula</article-title><source>Sci Rep</source><year>2025</year><volume>15</volume><issue>1</issue><fpage>9785</fpage><pub-id pub-id-type="doi">10.1038/s41598-025-90762-1</pub-id><?supplied-pmid 40118976?><pub-id pub-id-type="pmid">40118976</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wi YM, Choi JY, Lee DE, Jun SH, Kwon KT, Ko KS. Antimicrobial activity of cephamycins and &#x003b2;-lactam/&#x003b2;-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula. Sci Rep. 2025;15(1):9785. 10.1038/s41598-025-90762-1.<pub-id pub-id-type="pmid">40118976</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Nagao</surname><given-names>M</given-names></name><name><surname>Komori</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-&#x003b2;-lactamase-producing Escherichia coli bacteremia</article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>9</issue><fpage>5107</fpage><lpage>5113</lpage><pub-id pub-id-type="doi">10.1128/AAC.00701-15</pub-id><?supplied-pmid 26100708?><pub-id pub-id-type="pmid">26100708</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-&#x003b2;-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015;59(9):5107&#x02013;13. 10.1128/AAC.00701-15.<pub-id pub-id-type="pmid">26100708</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Tamma</surname><given-names>PD</given-names></name><name><surname>Rodriguez-Bano</surname><given-names>J</given-names></name></person-group><article-title>The use of noncarbapenem &#x003b2;-lactams for the treatment of extended-spectrum &#x003b2;-lactamase infections</article-title><source>Clin Infect Dis</source><year>2017</year><volume>64</volume><issue>7</issue><fpage>972</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1093/cid/cix034</pub-id><?supplied-pmid 28362938?><pub-id pub-id-type="pmid">28362938</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Tamma PD, Rodriguez-Bano J. The use of noncarbapenem &#x003b2;-lactams for the treatment of extended-spectrum &#x003b2;-lactamase infections. Clin Infect Dis. 2017;64(7):972&#x02013;80. 10.1093/cid/cix034. Pubmed:28362938.<pub-id pub-id-type="pmid">28362938</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2023.</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashiro</surname><given-names>H</given-names></name><name><surname>Kasamatsu</surname><given-names>Y</given-names></name><name><surname>Anan</surname><given-names>N</given-names></name><name><surname>Takemura</surname><given-names>M</given-names></name><name><surname>Yamano</surname><given-names>Y</given-names></name></person-group><article-title>In vitro efficacy of humanized regimen of flomoxef against extended-spectrum &#x003b2;-lactamase-producing Escherichia coli and Klebsiella pneumoniae</article-title><source>Antimicrob Agents Chemother</source><year>2023</year><volume>67</volume><issue>9</issue><fpage>e0025823</fpage><pub-id pub-id-type="doi">10.1128/aac.00258-23</pub-id><?supplied-pmid 37610203?><pub-id pub-id-type="pmid">37610203</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Yamashiro H, Kasamatsu Y, Anan N, Takemura M, Yamano Y. In vitro efficacy of humanized regimen of flomoxef against extended-spectrum &#x003b2;-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2023;67(9):e0025823. 10.1128/aac.00258-23.<pub-id pub-id-type="pmid">37610203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">JMDC Inc. JMDC real world. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.phm-jmdc.com/">https://www.phm-jmdc.com/</ext-link>.</mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Mireles</surname><given-names>AL</given-names></name><name><surname>Walker</surname><given-names>JN</given-names></name><name><surname>Caparon</surname><given-names>M</given-names></name><name><surname>Hultgren</surname><given-names>SJ</given-names></name></person-group><article-title>Urinary tract infections: epidemiology, mechanisms of infection and treatment options</article-title><source>Nat Rev Microbiol</source><year>2015</year><volume>13</volume><issue>5</issue><fpage>269</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3432</pub-id><?supplied-pmid 25853778?><pub-id pub-id-type="pmid">25853778</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269&#x02013;84. 10.1038/nrmicro3432. Pubmed:25853778.<pub-id pub-id-type="pmid">25853778</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>G</given-names></name><name><surname>Midiri</surname><given-names>A</given-names></name><name><surname>Gerace</surname><given-names>E</given-names></name><name><surname>Marra</surname><given-names>M</given-names></name><name><surname>Zummo</surname><given-names>S</given-names></name><name><surname>Biondo</surname><given-names>C</given-names></name></person-group><article-title>Urinary tract infections: the current scenario and future prospects</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><issue>4</issue><fpage>623</fpage><pub-id pub-id-type="doi">10.3390/pathogens12040623</pub-id><?supplied-pmid 37111509?><pub-id pub-id-type="pmid">37111509</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary tract infections: the current scenario and future prospects. Pathogens. 2023;12(4):623. 10.3390/pathogens12040623.<pub-id pub-id-type="pmid">37111509</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>E</given-names></name><name><surname>Glasner</surname><given-names>P</given-names></name><name><surname>Ranganathan</surname><given-names>S</given-names></name><name><surname>Swiatecka-Urban</surname><given-names>A</given-names></name></person-group><article-title>Tubulointerstitial nephritis: diagnosis, treatment, and monitoring</article-title><source>Pediatr Nephrol</source><year>2017</year><volume>32</volume><issue>4</issue><fpage>577</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1007/s00467-016-3394-5</pub-id><?supplied-pmid 27155873?><pub-id pub-id-type="pmid">27155873</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Joyce E, Glasner P, Ranganathan S, Swiatecka-Urban A. Tubulointerstitial nephritis: diagnosis, treatment, and monitoring. Pediatr Nephrol. 2017;32(4):577&#x02013;87.<pub-id pub-id-type="pmid">27155873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Kakaraskoska Boceska</surname><given-names>B</given-names></name><name><surname>Vilken</surname><given-names>T</given-names></name><name><surname>Xavier</surname><given-names>BB</given-names></name><name><surname>Kostyanev</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Lammens</surname><given-names>C</given-names></name><etal/></person-group><article-title>Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>3947</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-48296-z</pub-id><?supplied-pmid 38729951?><pub-id pub-id-type="pmid">38729951</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kakaraskoska Boceska B, Vilken T, Xavier BB, Kostyanev T, Lin Q, Lammens C, et al. Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries. Nat Commun. 2024;15(1):3947. 10.1038/s41467-024-48296-z. Pubmed:38729951.<pub-id pub-id-type="pmid">38729951</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Darlow</surname><given-names>CA</given-names></name><name><surname>Hope</surname><given-names>W</given-names></name></person-group><article-title>Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales</article-title><source>J Antimicrob Chemother</source><year>2021</year><volume>77</volume><issue>3</issue><fpage>711</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab468</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Darlow CA, Hope W. Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. J Antimicrob Chemother. 2021;77(3):711&#x02013;8.</mixed-citation></citation-alternatives></ref></ref-list></back></article>